BIO-acetoxime

667463-85-6

C18H12BrN3O3

DMSO : 20.83 mg/mL (52.31 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

Stem Cell/Wnt; PI3K/Akt/mTOR

BIO-acetoxime (BIA) is a potent and selective GSK-3 inhibitor, with IC₅₀s of both 10 nM for GSK-3alpha/beta. BIO-acetoxime has anticonvulsant and anti-infection activity. IC50 & Target: IC50: 10 nM (GSK-3alpha/beta) In Vitro: BIO-acetoxime (BIA; Compound 13) is a potent and selective GSK-3alpha/beta inhibitor, with IC₅₀s of both 10 nM. BIO-acetoxime (BIA) shows weak effect on CDK5/p35 (IC₅₀, 2.4 uM), CDK2/cyclin A (IC₅₀, 4.3 uM), and CDK1/cyclin B (IC₅₀, 63 uM)^[1]. BIO-acetoxime (BIA) (5 uM and 10 uM) increases the viability of HSV-1-infected cells but shows little effect on morphology and viability of mockin-fected cells. Moreover, BIO-acetoxime (BIA) (0.625, 1.25, 2.5, 5, and 10 uM) significantly reduces the release of HSV-1 particles in OC3 cells, with an EC₅₀ of 0.68 +/- 0.28 uM. BIO-acetoxime (BIA) inhibits the expression of HSV-1 genes, and may not affect the nuclear targeting of HSV-1 capsids. In addition, delayed addition of BIO-acetoxime (BIA) also inhibits HSV-1 infection^[2]. In Vivo: BIO-acetoxime (BIA) shows anticonvulsant effects in the focal pilocarpine rat model at 0.5 mg/kg, and in 6-Hz fully kindled FVB/N mice at 0.5, 2.5, and 5 mg/kg via i.p. administration^[3].